Showing 7 posts of 97 posts found.

arGEN-X appoints Alain Thibault as its new chief medical officer

March 19, 2012
Sales and Marketing Alain Thibault, Regeneron, arGEN-X

arGEN-X, a biopharma firm focused on the discovery and development of human monoclonal antibodies, has appointed Alain Thibault as the …

Eylea picture

Lucentis rival gains US approval

November 22, 2011
Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche

A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …

Sanofi eyes phase III move for sarilumab in rheumatoid arthritis

July 13, 2011
Research and Development Regeneron, Sanofi, ankylosing spondylitis, research and development news, rheumatoid arthritis, sarilumab

Sanofi is poised to move sarilumab into phase III trials for rheumatoid arthritis after the monoclonal antibody showed positive results …

Bayer submits Lucentis rival for European approval

June 7, 2011
Sales and Marketing Bayer, Lucentis, Regeneron, VEGF Trap-Eye

Bayer Healthcare has submitted its new eye drug to European regulators for approval to treat age-related macular degeneration (wet AMD). …

Sanofi lung cancer drug fails in late-stage trial

March 11, 2011
Research and Development Cancer, NSCLC, Regeneron, Sanofi-Aventis, aflibercept, non-small cell lung cancer

Sanofi-Aventis’ lung cancer drug aflibercept has failed to meet its primary endpoint in a phase III trial. The late-stage VITAL …

Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010
Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …


Sanofi expands antibody venture with Regeneron

November 12, 2009
Research and Development Regeneron, Sanofi

 Sanofi-Aventis has put more financial muscle behind its partnership with Regeneron for the development of monoclonal antibody-based drugs, boosting its …

Latest content